InfuSystem to be Acquired for $1 Billion
Ticker: INFU · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1337013
| Field | Detail |
|---|---|
| Company | Infusystem Holdings, INC (INFU) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, private-equity, merger
TL;DR
Patient Square Capital is buying InfuSystem for $1B, deal expected Q4 2024.
AI Summary
InfuSystem Holdings, Inc. announced on September 4, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Patient Square Capital. The transaction is valued at approximately $1.0 billion, representing a premium of 30% over the 30-day volume-weighted average price of InfuSystem's common stock as of September 3, 2024. The deal is expected to close in the fourth quarter of 2024.
Why It Matters
This acquisition by Patient Square Capital signifies a major financial event for InfuSystem, potentially leading to delisting and changes in its operational structure.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could impact the completion of the deal.
Key Numbers
- $1.0B — Acquisition Value (Total price Patient Square Capital is paying for InfuSystem.)
- 30% — Premium (The percentage premium over the 30-day VWAP offered in the acquisition.)
Key Players & Entities
- InfuSystem Holdings, Inc. (company) — Company being acquired
- Patient Square Capital (company) — Acquiring entity
- $1.0 billion (dollar_amount) — Acquisition valuation
- September 4, 2024 (date) — Announcement date
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement?
The acquisition agreement values InfuSystem Holdings, Inc. at approximately $1.0 billion.
Who is acquiring InfuSystem Holdings, Inc.?
An affiliate of Patient Square Capital is acquiring InfuSystem Holdings, Inc.
When is the acquisition expected to be completed?
The transaction is expected to close in the fourth quarter of 2024.
What is the premium offered in the acquisition?
The acquisition represents a premium of 30% over the 30-day volume-weighted average price of InfuSystem's common stock as of September 3, 2024.
What are the conditions for closing the acquisition?
The acquisition is subject to customary closing conditions, including regulatory approvals.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-09-04 06:31:28
Filing Documents
- infu-20240904.htm (8-K) — 28KB
- exhibit99109-04x2024lakest.htm (EX-99.1) — 13KB
- infusystem_safesmarttruste.jpg (GRAPHIC) — 760KB
- 0001628280-24-039215.txt ( ) — 1205KB
- infu-20240904.xsd (EX-101.SCH) — 2KB
- infu-20240904_lab.xml (EX-101.LAB) — 21KB
- infu-20240904_pre.xml (EX-101.PRE) — 12KB
- infu-20240904_htm.xml (XML) — 3KB
01 - Regulation FD Disclosure
Item 7.01 - Regulation FD Disclosure On September 4, 2024 , InfuSystem Holdings, Inc. (the "Company") issued a press release announcing that Richard DiIorio, Chief Executive Officer and Barry Steele, Chief Financial Officer will participate in Lake Street Capital Markets' 8 th Annual Best Ideas Growth (BIG8) Conference on Thursday, September 12, 2024. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 7.01 — "Regulation FD Disclosure" of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of such section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of InfuSystem Holdings, Inc. dated September 4 , 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INFUSYSTEM HOLDINGS, INC. By: /s/ Barry Steele Barry Steele Chief Financial Officer Dated: September 4, 2024